- Home
- BNRG vs KPRX Comparison
BNRG vs KPRX Comparison
Compare BNRG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- KPRX
- Stock Information
- Founded
- BNRG 2012
- KPRX 1998
- Country
- BNRG Israel
- KPRX United States
- Employees
- BNRG N/A
- KPRX N/A
- Industry
- BNRG
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BNRG
- KPRX Health Care
- Exchange
- BNRG Nasdaq
- KPRX Nasdaq
- Market Cap
- BNRG 14.7M
- KPRX 12.0M
- IPO Year
- BNRG 2022
- KPRX N/A
- Fundamental
- Price
- BNRG $1.45
- KPRX $3.47
- Analyst Decision
- BNRG
- KPRX Strong Buy
- Analyst Count
- BNRG 0
- KPRX 1
- Target Price
- BNRG N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BNRG 396.4K
- KPRX 46.3K
- Earning Date
- BNRG 03-03-2025
- KPRX 03-24-2025
- Dividend Yield
- BNRG N/A
- KPRX N/A
- EPS Growth
- BNRG N/A
- KPRX N/A
- EPS
- BNRG N/A
- KPRX 1.69
- Revenue
- BNRG $41,000.00
- KPRX $16,020,000.00
- Revenue This Year
- BNRG N/A
- KPRX N/A
- Revenue Next Year
- BNRG N/A
- KPRX N/A
- P/E Ratio
- BNRG N/A
- KPRX $2.05
- Revenue Growth
- BNRG N/A
- KPRX N/A
- 52 Week Low
- BNRG $0.60
- KPRX $3.00
- 52 Week High
- BNRG $4.11
- KPRX $6.75
- Technical
- Relative Strength Index (RSI)
- BNRG 51.50
- KPRX 44.69
- Support Level
- BNRG $1.02
- KPRX $3.40
- Resistance Level
- BNRG $1.43
- KPRX $3.75
- Average True Range (ATR)
- BNRG 0.18
- KPRX 0.22
- MACD
- BNRG 0.01
- KPRX -0.03
- Stochastic Oscillator
- BNRG 63.24
- KPRX 37.65
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is an Israel-based company. It is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.